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Abstract
Introduction: The intrinsic heterogeneity of clinical septic shock is a major challenge. For clinical trials, individual
patient management, and quality improvement efforts, it is unclear which patients are least likely to survive and
thus benefit from alternative treatment approaches. A robust risk stratification tool would greatly aid decision-
making. The objective of our study was to derive and test a multi-biomarker-based risk model to predict outcome
in pediatric septic shock.
Methods: Twelve candidate serum protein stratification biomarkers were identified from previous genome-wide
expression profiling. To derive the risk stratification tool, biomarkers were measured in serum samples from 220
unselected children with septic shock, obtained during the first 24 hours of admission to the intensive care unit.
Classification and Regression Tree (CART) analysis was used to generate a decision tree to predict 28-day all-cause
mortality based on both biomarkers and clinical variables. The derived tree was subsequently tested in an
independent cohort of 135 children with septic shock.
Results: The derived decision tree included five biomarkers. In the derivation cohort, sensitivity for mortality was
91% (95% CI 70 - 98), specificity was 86% (80 - 90), positive predictive value was 43% (29 - 58), and negative
predictive value was 99% (95 - 100). When applied to the test cohort, sensitivity was 89% (64 - 98) and specificity
was 64% (55 - 73). In an updated model including all 355 subjects in the combined derivation and test cohorts,
sensitivity for mortality was 93% (79 - 98), specificity was 74% (69 - 79), positive predictive value was 32% (24 - 41),
and negative predictive value was 99% (96 - 100). False positive subjects in the updated model had greater illness
severity compared to the true negative subjects, as measured by persistence of organ failure, length of stay, and
intensive care unit free days.
Conclusions: The pediatric sepsis biomarker risk model (PERSEVERE; PEdiatRic SEpsis biomarkEr Risk modEl) reliably
identifies children at risk of death and greater illness severity from pediatric septic shock. PERSEVERE has the
potential to substantially enhance clinical decision making, to adjust for risk in clinical trials, and to serve as a septic
shock-specific quality metric.
Introduction
In developed countries with ready access to powerful
antibiotics and modern intensive care units, septic shock
continues to be a major cause of morbidity and mortality
in both adult and pediatric populations [1-4]. Experimen-
tal therapies continue to be evaluated. Yet, despite being
based on sound biological principles and pre-clinical
data, the majority of experimental therapies fail when
tested in randomized, controlled trials [5]. While failure
is likely multi-factorial, one consistent confounder is that
septic shock is not a simple disease with uniform expres-
sion across a given patient cohort. Rather, septic shock is
a complex syndrome displaying a tremendous degree of
heterogeneity. It has been proposed that our inability to
manage this heterogeneity is a major challenge for effec-
tive and rational clinical trials, and that a robust risk stra-
tification tool could overcome this challenge [5,6].* Correspondence: hector.wong@cchmc.org1Division of Critical Care Medicine, Cincinnati Children’s Hospital Medical
Center and Cincinnati Children’s Research Foundation, Cincinnati, OH, USA
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We have been searching for biomarkers that might be
associated with outcomes in pediatric septic shock using
genome-wide expression profiling [7-17]. Through this
discovery-oriented approach, we previously identified a
panel of candidate stratification gene probes to predict
outcome [18,19]. Twelve of these gene probes translate to
readily measured serum protein biomarkers with known
biological mechanisms suggesting a possible association
with outcomes from septic shock. Our goal was to use
these biomarkers to derive a risk stratification tool to iden-
tify those children with septic shock who are least likely to
survive. Using classification and regression tree (CART)
analysis, we derived and tested the Pediatric Sepsis Bio-
marker Risk Model (PERSEVERE).
Materials and methods
Patients, samples, and data collection
The study protocol was approved by the Institutional
Review Boards of each of the 17 participating institutions.
The data collection protocol was identical for both the
derivation and test cohorts, and has been described in
detail [12]. Briefly, children < 11 years of age admitted to
a pediatric intensive care unit (PICU) and meeting pedia-
tric-specific criteria for septic shock were eligible [20].
Full-term neonates (that is, < 28 days of age) re-admitted
to the hospital for septic shock were included. Clinical
care was not directed by the study, and except for when
informed consent could not be obtained, no child was
excluded. After informed consent was obtained from par-
ents or legal guardians, and within 24 hours of admission
to the PICU, serum samples were obtained. Annotated
clinical and laboratory data were collected daily while the
participant was in the PICU. Illness severity was prospec-
tively calculated using the pediatric risk of mortality
(PRISM) score [21]. The number of organ failures during
the initial 7 days of PICU admission was recorded using
pediatric-specific criteria [20]. PICU-free days were cal-
culated by subtracting the actual PICU length of stay
(LOS) from a theoretical maximum PICU LOS of 28
days. Patients with a PICU LOS greater than 28 days
were classified as having zero PICU-free days. The pri-
mary outcome variable was all-cause 28-day mortality.
Candidate biomarkers
The 12 candidate biomarkers (gene symbols) included:
C-C chemokine ligand 3 (CCL3), C-C chemokine ligand
4 (CCL4), neutrophil elastase 2 (ELA2), granzyme B
(GZMB), heat shock protein 70 kDa 1B (HSPA1B),
interleukin 1a (IL1A), interleukin 8 (IL8), lipocalin 2
(LCN2), lactotransferrin (LTF), matrix metalloproteinase
8 (MMP8), resistin (RETN), and thrombospondin 1
(THBS1). These were selected from 117 gene probes
demonstrating outcome predictive strength in microar-
ray-based studies involving children with septic shock
[18,19]. The serum concentrations of the candidate bio-
markers were measured using a multiplex magnetic
bead platform (MILLIPLEX™ MAP) designed for this
project by the EMD Millipore Corporation (Billerica,
MA, USA). Biomarker concentrations were measured in
a Luminex® 100/200 System (Luminex Corporation,
Austin, TX, USA), according to the manufacturers’ spe-
cifications. Assay performance data are provided in
Additional File 1.
Statistical analysis
Initially, data were described using medians, interquartile
ranges (IQR), frequencies, and percents. Comparisons
between survivors and non-survivors were performed
using the Mann-Whitney U-test, Chi-square test, or Fish-
er’s Exact test as appropriate. Analysis of descriptive sta-
tistics and comparisons were performed using SigmaStat
Software (Systat Software, Inc., San Jose, CA, USA).
To derive the decision tree, we employed a classification
and regression tree (CART) approach for the determina-
tion of biomarker cutoffs [22]. All 12 candidate biomar-
kers, as well as age and gender were considered in the
CART analysis. The classification tree was built using
Salford Predictive Modeler v6.6 (Salford Systems, San
Diego, CA, USA). The model parameters, pruning criteria,
and the command file for reproducing the classification
tree are provided in Additional File 2. Performance of the
decision tree is reported using diagnostic test statistics
with 95% confidence intervals computed using the score




The demographics and clinical characteristics of the
derivation cohort (n = 220) are provided in Table 1.
The 23 (10.5%) non-survivors had a higher median
PRISM score compared to the 197 survivors. Age, gen-
der, race, infection characteristics, and occurrence of
comorbidities did not differ significantly between survi-
vors and non-survivors. The mean ± SD and median
(IQR) times to death in the derivation cohort non-
survivors were 6.1 ± 7.5 and 2 (1 to 8) days, respectively.
A complete list of comorbidities for the survivors in the
derivation cohort is provided in Additional File 3. A list
of causative organisms for the derivation cohort is pro-
vided in Additional File 4.
The derived decision tree is shown in Figure 1. Maxi-
mum accuracy was achieved with five of the twelve can-
didate stratification biomarkers: CCL3, HSPA1B, IL8,
ELA2, and LCN2. No demographic or clinical variables
improved predictive accuracy. There were three low-risk
terminal nodes (≤ 1.5% risk of death; nodes 5, 8, and 9)
and three high-risk terminal nodes (≥ 40% risk of death;
Wong et al. Critical Care 2012, 16:R174
http://ccforum.com/content/16/5/R174
Page 2 of 9
nodes 2, 4, and 10). Of the 171 participants classified as
low-risk, 169 survived and 2 (1.2%) had died by 28 days.
Of the 49 participants classified as high risk, 21 (42.9%)
had died by 28 days. The diagnostic test characteristics
are shown in Table 2.
Testing PERSEVERE
The independent test cohort consisted of 135 partici-
pants with septic shock, of whom 18 (13.3%) did not sur-
vive to 28 days. Table 3 provides the demographic and
clinical characteristics of the test cohort. Compared to
the derivation cohort, the test cohort had a higher pro-
portion of Caucasians and a greater proportion with no
causative organism isolated. The test cohort also had a
lower proportion with no reported race and a lower pro-
portion with gram-positive bacteria, compared to the
derivation cohort. The test and derivation cohorts were
otherwise not statistically different. Within the test
cohort, there were no significant differences between sur-
vivors and non-survivors, except for the median PRISM
scores. The mean and median times to death in the test
cohort non-survivors were 9.9 ± SD 11.2 and 4 (IQR 2 to
16) days, respectively. A complete list of comorbidities
for the survivors in the test cohort is provided in Addi-
tional File 3. A list of causative organisms for the test
cohort is provided in Additional File 4.
The classification of the test cohort participants
according to the decision tree is shown in Additional
File 5. Seventy-seven patients were classified as low risk
(nodes 5 and 8), while 58 were classified as high risk
(nodes 2, 4, and 10). Among the low-risk participants,
the mortality rate was 2.6%, while among the high-risk
participants the mortality rate was 27.6%. The diagnostic
test characteristics of the decision tree in the test cohort
are shown in Table 2.
Secondary considerations
The classification tree was updated using all 355 partici-
pants in the combined derivation and test cohorts. The
model parameters, pruning criteria, and the command
file for reproducing the updated classification tree are
provided in Additional File 6. All 12 candidate biomar-
kers, as well as age and gender were considered in the
updating process. The updated decision tree is shown in
Figure 2. Maximum accuracy was achieved with three of
the same stratification biomarkers (CCL3, HSPA1B, and
IL8), while the importance of ELA2 and LCN2 were
superseded by GZMB and MMP8. Age also added to the
predictive capacity of the updated tree (nodes 13 and 14).
There were three low-risk terminal nodes (0.0 to 2.5%
risk of death; nodes 7, 11, and 14) and five high-risk
terminal nodes (18.2 to 62.5% risk of death; nodes 4, 8,
10, 12, and 13). Of the 236 participants classified as low
risk, 233 survived (98.7%) and 3 had died (1.3%) by
28 days. Of the 119 participants classified as high risk, 38
had died (31.9%) by 28 days. The diagnostic test
Table 1 Demographics and clinical characteristics of the derivation cohort
All Survivors Non-survivors
Number of subjects 220 197 23
Median age in years (25%, 75%)1 2.2 (0.8, 5.9) 2.3 (1.0, 5.9) 1.4 (0.2, 4.2)
Median PRISM score (25%, 75%) 15 (8, 22) 13 (7, 20) 28 (20, 37)2
Number of males (%) 137 (62) 120 (61) 17 (74)
Number of females (%) 83 (38) 77 (39) 6 (26)

















Number with gram (+) bacteria (%) 70 (32) 61 (31) 9 (39)
Number with gram (-) bacteria (%) 55 (25) 51 (26) 4 (17)
Number with viral infection (%) 16 (7) 13 (7) 3 (13)
Number with fungal infection (%) 7 (3) 6 (3) 1 (4)
Number with no organism isolated (%) 72 (33) 66 (34) 6 (26)
Number with any co-morbidity (%) 91 (41) 82 (42) 9 (39)4
Number with meningitis (%) 12 (5) 10 (5) 2 (9)
Number with cancer (%) 17 (5) 17 (9) 0 (0)
Number with immune suppression (%)5 16 (7) 13 (7) 3 (13)
1Two subjects in the derivation cohort were older than stated in the protocol (13 and 14 years of age) but were included in the analysis. 2P < 0.001 vs. survivors.
3Includes Asian, multi-racial, native Hawaiian/Pacific Islander, and American Indian. 4Co-morbidities in non-survivors included anti-phospholipid antibody
syndrome; aplastic anemia; chronic lung disease (2 subjects); DiGeorge Syndrome; developmental delay (2 subjects); hypoplastic left heart syndrome; and short
gut syndrome. 5Refers to patients with immune suppression not related to cancer (for example, those receiving immune suppressive medication for solid organ
transplantation, or those with a primary immune deficiency).
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characteristics of the updated decision tree are shown in
Table 2.
If PERSEVERE is clinically relevant and biologically plau-
sible, then one could postulate that the 81 false-positive
participants in the updated decision tree (that is, Those
predicted to be non-survivors, but were actually survi-
vors) would demonstrate an increased degree of organ
dysfunction and PICU LOS, and less PICU-free days,
compared to the 233 true-negative participants (that is,
those predicted to be survivors and were actually survi-
vors). Thirty percent of the false-positive participants had
persistence of two or more organ failures at 7 days after
study entry, compared to only 9% of the true-negative
participants (P < 0.001). The median (IQR) PICU LOS
for the false positive participants was 11 (6 to 17) days,
compared to 7 (4 to 12) days for the true-negative parti-
cipants (P = 0.003). Additionally, 64% of the false-positive
participants had a PICU LOS > 1 week, compared to 46%
of the true-negative participants (P = 0.01). The median
PICU-free days for the false-positive participants was 18
(12 to 23) days, compared to 21 (16 to 25) days for the
true-negative participants (P = 0.006). Additionally, 58%
of the false-positive participants had < 21 PICU-free
days, compared to 44% of the true-negative participants
(P = 0.025).
Discussion
We have derived and tested a biomarker-based risk stra-
tification tool, PERSEVERE, which appears to reliably
predict mortality in children with septic shock. PERSE-
VERE was derived using CART analysis, a potentially
powerful approach for discovering complex predictor
variable interactions that may not be evident using more
traditional approaches [22,24]. The major drawback of
Figure 1 Classification tree from the derivation cohort (n = 220). The classification tree consists of five biomarker-based decision rules and
ten daughter nodes. The classification tree includes five of the twelve candidate stratification biomarkers: C-C chemokine ligand 3 (CCL3), heat
shock protein 70 kDa 1B (HSPA1B), interleukin-8 (IL8), elastase 2 (ELA2), and lipocalin 2 (LCN2). Each node provides the total number of subjects
in the node, the biomarker serum concentration-based decision rule, and the number of survivors and non-survivors with the respective rates.
For consistency, the serum concentrations of all stratification biomarkers are provided in pg/ml. Terminal nodes 5, 8, and 9 are considered low-
risk nodes, whereas terminal nodes 2, 4, 10 are considered high-risk terminal nodes. To calculate the diagnostic test characteristics, all subjects in
the low-risk terminal nodes (n = 171) were classified as predicted survivors, whereas all subjects in the high-risk terminal nodes (n = 49) were
classified as predicted non-survivors. The area under the curve (AUC) for the derivation cohort tree was 0.885.
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CART analysis is the potential to over-fit a given dataset.
Consequently, it is imperative that CART-derived models
be tested using an independent dataset. When we applied
PERSEVERE to an independent cohort of children with
septic shock, those predicted as non-survivors had more
than 25% mortality by 28 days. Additionally, the high-risk
survivors in the updated model were found to have a
greater degree of illness severity as measured by persis-
tence of organ failure, PICU LOS, and PICU-free days.
A major strength of PERSEVERE is the initial approach
to deriving the candidate biomarkers [18,19]. Using our
extensive genome-wide expression databank, we objec-
tively selected 12 of the 117 gene probes possibly asso-
ciated with outcome in a cohort of children with septic
shock. The selection criteria defined a priori were that: 1)
the gene product (that is, protein) must have biological
and mechanistic plausibility regarding the host response
to infection, immunity, and/or inflammation, and 2) the
gene product must be capable of being readily measured
in the serum compartment. Accordingly, the selection of
the candidate biomarkers was a relatively unbiased
process, although we recognize some might consider
Table 2 Performance of the classification trees
Derivation cohort Test cohort Updated model
Number of subjects 220 135 355
Number of true positives 21 16 38
Number of true negatives 169 75 233
Number of false positives 28 42 81
Number of false negatives 2 2 3
Sensitivity 91% (70, 98) 89% (64, 98) 93% (79, 98)
Specificity 86% (80, 90) 64% (55, 73) 74% (69, 79)
Positive predictive value 43% (29, 58) 28% (17, 41) 32% (24, 41)
Negative predictive value 99% (95, 100) 97% (90, 100) 99% (96, 100)
+Likelihood ratio 6.4 (4.5, 9.3) 2.5 (1.8, 3.3) 3.6 (2.9, 4.4)
-Likelihood ratio 0.1 (0.0, 0.4) 0.2 (0.0, 0.6) 0.1 (0.0, 0.3)
Area under the curve 0.885 0.759 0.883
Table 3 Demographics and clinical characteristics of the test cohort
All Survivors Non-survivors
Number of subjects 135 117 18
Median age in years (25%, 75%) 2.8 (1.0, 6.7) 2.7 (1.0, 6.7) 3.8 (0.9, 7.7)
Median PRISM score (25%, 75%) 13 (7, 19) 12 (7, 18) 23 (14, 32)1
Number of males (%) 70 (52) 63 (54) 7 (39)
Number of females (%) 65 (48) 54 (46) 11 (61)
Number for race (%)
Caucasian 113 (84)2 99 (85) 14 (78)
African American 15 (11) 13 (11) 2 (11)
Other3 6 (4) 4 (3) 2 (11)
Unreported 1 (1)2 1 (1) 0 (0)
Number with gram (+) bacteria (%) 27 (20)2 24 (21) 3 (17)
Number with gram (-) bacteria (%) 27 (20) 22 (19) 5 (28)
Number with viral infection (%) 10 (7) 9 (8) 1 (6)
Number with fungal infection (%) 2 (1) 2 (2) 0 (0)
Number with no organism isolated (%) 72 (53)2 63 (54) 9 (50)
Number with any co-morbidity (%) 52 (39) 45 (38) 7 (39)4
Number with meningitis (%) 5 (4) 3 (3) 2 (11)
Number with cancer (%) 17 (13) 14 (12) 3 (17)
Number with immune suppression (%)5 13 (10) 13 (11) 0 (0)
1P = 0.001 vs. survivors. 2P <0.05 for test cohort vs. derivation cohort. 3Includes Asian, multi-racial, native Hawaiian/Pacific Islander, and American Indian. 4Co-
morbidities in non-survivors included acute myeloid leukemia; atrial and ventricular septal defects; fulminant hepatic failure; hypoplastic left heart syndrome;
short gut syndrome; neuroblastoma; and optic nerve glioma. 5Refers to patients with immune suppression not related to cancer (for example, those receiving
immune suppressive medication for solid organ transplantation, or those with a primary immune deficiency).
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assertion of biological and mechanistic plausibility and
the technical limitation of being able to measure the pro-
tein in the serum compartment as causes of bias.
Another strength of PERSEVERE is its potential for gen-
eralizability. The PERSEVERE derivation and test cohorts
represent 17 different institutions throughout the USA.
Participant eligibility was unrestricted and enrollment was
based exclusively on pediatric-specific criteria for septic
shock. The only exclusion criterion was the inability to
obtain informed consent. Consequently, the study cohorts
represent the entire spectrum of pediatric septic shock,
including patients with a broad range of significant co-
morbidities typically encountered in clinical practice. In
addition, the mortality rate and illness severity in this
study are consistent with published studies [4,25,26].
Because clinical care was not under protocol, PERSEVERE
appears to be independent of variability in local clinical
practice patterns and nuances. We contend that these fea-
tures will allow for feasible application of PERSEVERE in
clinical practice.
We are not aware of a validated stratification tool for
pediatric septic shock that performs in an equivalent
manner to that of PERSEVERE. We previously proposed
and tested a cutoff value for serum IL8 having a 95%
negative predictive value (NPV) for mortality in pediatric
septic shock [27]. However, the sensitivity, specificity,
and positive predictive value (PPV) of IL8 in isolation
were substantially lower than that of PERSEVERE. Three
Figure 2 Classification tree from the updated model based on the combined derivation and test cohorts (n = 355). The classification
tree consists of six biomarker-based decision rules, one age-based decision rule, and fourteen daughter nodes. The classification tree includes
five of the twelve candidate stratification biomarkers: C-C chemokine ligand 3 (CCL3), heat shock protein 70 kDa 1B (HSPA1B), interleukin-8 (IL8),
granzyme B (GZMB), and matrix metalloproteinase-8 (MMP8). Each node provides the total number of subjects in the node, the biomarker serum
concentration- or age-based decision rule, and the number of survivors and non-survivors with the respective rates. For consistency, the serum
concentrations of all stratification biomarkers are provided in pg/ml. Terminal nodes 7, 11, and 14 are considered low-risk nodes, whereas
terminal nodes 4, 8, 10, 12, and 13 are considered high-risk terminal nodes. To calculate the diagnostic test characteristics, all subjects in the low
risk terminal nodes (n = 236) were classified as predicted survivors, whereas all subjects in the high risk terminal nodes (n = 119) were classified
as predicted non-survivors. The area under the curve (AUC) for the re-calibrated decision tree was 0.883.
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biomarkers (CCL3, HSPA1B, and IL8) appear to be the
primary predictors in PERSEVERE. These three biomar-
kers consistently contribute to the upper level decision
rules of both the initially derived tree and the subsequent
updated tree. The lower-level decision rules appear to be
less clear. ELA2 and LCN2 contributed to predictive
capacity in the initially derived tree, but not in the subse-
quent updated tree, which instead included GZMB,
MMP8, and age. Notably, members of our group are cur-
rently pursuing GZMB [28,29] and MMP8 [14] as novel
therapeutic targets in septic shock, and younger age was
previously linked to higher mortality in pediatric septic
shock [4]. We expect that including additional patients in
future modeling procedures will further define the com-
ponents of the lower-level decision rules.
Illness severity scores (such as PRISM) are robust for
predicting the outcome of general ICU populations, but
are not intended for stratification and are not septic
shock-specific [30]. Nonetheless, we expect there will be
interest in comparing PERSEVERE performance with
that of PRISM. As shown in Additional File 7, the
updated model has a higher area under the curve than
PRISM. In addition, at a comparable sensitivity of 93%,
the PPV and specificity of PERSEVERE are 2-fold higher
than that of PRISM.
An overall 32% PPV for mortality in the updated model
may be viewed as being relatively low. However, PPV is
highly influenced by prevalence and consequently needs to
be interpreted in the context of prevalence [19]. In our
study cohort, overall mortality was 11%. Therefore, the
model identifies a cohort (namely, high-risk patients) with
a mortality rate that is almost 3-fold higher than the over-
all cohort mortality. In addition, the model identifies a
cohort (namely, low-risk patients) with an overall morality
of 1%. Thus, at its most basic level, PERSEVERE divides
the overall cohort into two populations having a 30-fold
difference in mortality.
We envisage several applications of PERSEVERE. First, it
could be used to select participants for interventional clini-
cal trials. Excluding participants with very low mortality
risk, while simultaneously selecting those at greatest mor-
tality risk, increases the magnitude of possible survival
benefit of a new therapy, while not placing those most
likely to survive at risk of any adverse effects of a new
therapeutic approach. Based on the test characteristics of
the updated model, PERSEVERE has the potential to
exclude patients, having up to a 99% probability of survival
with standard care, and include patients with up to a 32%
probability of death. The latter is clinically relevant given
that the best available epidemiological data indicate an
overall mortality of about 10% for pediatric septic shock in
the USA [1,4]. The largest pediatric septic shock interven-
tional trial to date employed a surrogate primary outcome
variable because power calculations based on an assumed
mortality rate of 12% would have required more than
3,000 subjects to achieve sufficient power to detect an
absolute decrease in mortality of 2% [25]. Beginning with a
cohort at higher predicted risk of mortality would have
allowed greater flexibility in study design, with the target
of a larger absolute risk reduction, and hence a smaller
sample size. By stratifying patients via PERSEVERE, one
has the potential to optimize the risk-to-benefit ratio of a
test agent having more than minimal risk, and conse-
quently conduct more rational clinical trials. Importantly,
PERSEVERE was developed using serum collected during
the first 24 hours of admission to the PICU, which is the
optimal period for initiating new therapeutic approaches,
and thus for risk-stratifying patients. If PERSEVERE is not
used to determine eligibility, it could be taken into account
by conducting a stratified outcomes analysis.
Outside of the clinical trial context, PERSEVERE could
help inform clinical decisions regarding the application of
high risk, invasive therapeutic and support modalities in
septic shock, such as extracorporeal life support, plasma-
pheresis, and pulmonary artery catheterization. Finally,
PERSEVERE has the potential to serve as a benchmark for
septic shock-specific quality improvement and quality
assurance efforts. For example, based on the updated
model, higher than 1% mortality in the lowest-risk patients
might be an indicator of poor performance, while lower
than 32% mortality in the highest-risk group might be
indicative of good performance. Moreover, differences in
illness severity in those who survived but who were pre-
dicted to die, and in those who survived and were pre-
dicted to survive, could provide some clues to tailoring
treatments to improve outcomes for all pediatric septic
shock patients.
We envisage that PERSEVERE will be dynamic and
require periodic updating. As we include more patients into
the modeling process, some of the biomarker cutoff values
that drive the decision tree may change. It is also possible
that new biomarkers are identified that might contribute to
the decision tree, or that previously tested biomarkers
might be useful for refining the risk stratification. This evo-
lution would enhance predictive performance and further
increase generalizability of the decision tree. These asser-
tions are evident in the updating process involving the
combined derivation and test cohorts. Finally, we also envi-
sage that PERSEVERE could provide the foundation for
deriving an analogous stratification model for adult septic
shock.
A potential weakness of PERSEVERE is that it is
focused on relatively short-term outcomes and does not
evaluate longer-term outcomes. Twenty-eight day all-
cause mortality has been a standard primary outcome
measure for multiple septic shock interventional clinical
trials, but its usefulness has been questioned and there is
increasing recognition that septic shock has significant
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negative consequences for quality of life beyond the
dichotomy of the patient being alive or dead at 28 days
[1,5]. The PERSEVERE protocol was not specifically
designed to assess longer-term outcomes. However, the
increased illness severity found in the false-positive
patients, compared to the true-negative patients, indir-
ectly suggests that PERSEVERE may have the capability
of stratifying longer-term outcomes, but this assertion
requires formal testing. We maintain that 28 day mortal-
ity remains a clinically relevant outcome variable in clini-
cal septic shock; at the very least, one must be alive
beyond 28 days in order to assess longer-term outcomes.
Another potential weakness of our study is that it is
difficult to unambiguously assign septic shock as the pri-
mary cause of death in all non-survivors. However, all-
cause mortality is a common outcome variable in septic
shock clinical trials, and the distribution of co-morbid-
ities across the survivors and non-survivors indirectly
suggests that many of the deaths could be, at least par-
tially, attributed to septic shock per se.
Conclusions
We have derived and successfully tested a biomarker-
based risk model to stratify pediatric septic shock out-
come. The basis of the model is a high throughput, rela-
tively unbiased, microarray-based approach, and the
derivation and test cohorts well represent the intrinsic het-
erogeneity and broad spectrum of pediatric septic shock
encountered in clinical practice. We propose that PERSE-
VERE has the potential to substantially enhance the con-
duct of clinical trials, inform clinical decision making, and
serve to inform septic shock-specific quality improvement
measures.
Key messages
• We have derived a multi-biomarker-based risk model
to predict outcome in pediatric septic shock.
• The derived model has been successfully tested in a
separate cohort.
• An updated model has a PPV for mortality of 32%
and a NPV of 99%, thus generating two cohorts having
a 30-fold difference in mortality.
• False-positive patients have a greater level of illness
severity than true-negative patients as measured by
organ failure, length of stay, and ICU-free days.
• The risk model has potential applications for clinical
trial stratification, individual patient decision making,
and quality assurance efforts.
Additional material
Additional File 1: Performance data for the biomarker assays. This
file provides technical data regarding the development of the biomarker
assays.
Additional File 2: Derivation of the classification tree using Salford
Predictive Modeler v6.6. This file provides the model parameters,
pruning criteria, and the command file for generating the decision tree.
Additional File 3: List of comorbidities in survivors for the
derivation and test cohorts. This file contains Table S1, which provides
a list of co-morbidities for patients (survivors) in the derivation and test
cohorts.
Additional File 4: Causative organisms for derivation and test
cohorts. This file contains Table S2, which provides a list of causative
organisms for patients in the derivation and test cohorts.
Additional File 5: Figure S1 that demonstrates the classification of
the test cohort patients according to the derived decision tree.
Classification tree for the test cohort (n = 135). The biomarker-based
decision rules from the derivation cohort tree were applied to the test
cohort with no modifications. The same conventions that were applied
to the derivation cohort for calculating diagnostic test characteristics
were applied to the test cohort, except that no patients in the test
cohort occupied low risk terminal node 9. The area under the curve for
the test cohort tree was 0.759.
Additional File 6: Updating the classification tree using Salford
Predictive Modeler v6.6. This file provided the model parameters,
pruning criteria, and the command file for generating the updated
decision tree.
Additional File 7: Comparison of PERSEVERE and PRISM for
predicting mortality in the combined derivation and test cohorts.
This file contains Table S3, which compares the test characteristics of
PERSEVERE and PRISM.
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